SEC Form 4 · accession 0001209191-15-053778
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jun 12, 2015
Accepted (ET)
Jun 16, 2015 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 12, 2015 | S | 5,919 | $14.20 | D | 4,561,393 | D | |
| Common StockF1 | Jun 15, 2014 | S | 14,777 | $14.20 | D | 4,546,616 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares are directly owned by Novartis BioVentures Ltd. Novartis BioVentures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.